There is one clinical trial.

Clinical Trials

1 Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation

TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in patients with COVID-19 infection. These results will lead to and inform a Phase III randomized placebo-controlled trial.

NCT04365153 COVID-19 SARS-CoV 2 Drug: Canakinumab Injection 600mg Drug: Canakinumab Injection 300mg Drug: Placebos

No related HPO nodes (Using clinical trials)